Fresenius Medical Care

Fresenius Medical Care AG & Co. KgaA provides products and services for individuals with renal diseases. The firm develops and manufactures health care products, which includes dialysis and non-dialysis products. It operates through the following segments: North America Segment, EMEA Segment, Asia-Pacific Segment and Latin America Segment. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

KINSTON, N.C. , Oct. 11, 2023 /PRNewswire/ -- Capital Square, one of the nation's leading sponsors of tax-advantaged real estate investments and an active developer of multifamily communities, announced today the sale of a medical building in Kinston, North Carolina.

Capital Square Delivers 147.63% Total Return* to Investors in Medical Building DST

Baxter

Intuitive Surgical

Boston Scientific

The trial success of Novo Nordisk's hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday.

Dialysis company shares plunge after Ozempic trial success vs. kidney trouble

Fresenius Medical (FMS) gets FDA clearance for Versi HD with GuideMe Software, a portable, home hemodialysis device with an easy-to-use graphical interface providing easier training experiences.

Fresenius Medical's (FMS) New HHD Device to Increase Portability

WALTHAM, Mass. , Aug. 23, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance for Versi®HD with GuideMe Software, a completely reinvented self-guided interface for the company's VersiHD chronic home hemodialysis (HHD) system.

Fresenius Medical Care Announces FDA Clearance of Versi®HD with GuideMe Software

The new partnership delivers care for hemodialysis patients at their local hospital, who previously had to travel nearly 100 miles for care, eliminating the need to be transferred to a more urban hospital. WALTHAM, Mass.

Fresenius Medical Care Partners with Sarah Bush Lincoln to Provide Life-Sustaining Care to Rural Patients

Fresenius Medical's (FMS) second-quarter revenues benefit from strong performance across all segments. Inflationary pressure continues to improve, benefiting operating income.

Fresenius Medical (FMS) Q2 Earnings and Revenues Beat Estimates

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS ) Q2 2023 Earnings Conference Call August 2, 2023 9:30 AM ET Company Participants Dominik Heger - Head of Investor Relations Helen Giza - Chief Executive Officer and acting Chief Financial Officer Conference Call Participants Victoria Lambert - Berenberg Veronika Dubajova - Citi Richard Felton - Goldman Sachs Hassan Al-Wakeel - Barclays Oliver Metzger - ODDO BHF James Vane-Tempest - Jefferies International Limited Lisa Clive - A.D. Bernstein David Adlington - JPMorgan Christoph Gretler - Credit Suisse Falko Friedrichs - Deutsche Bank Hugo Solvet - BNP Paribas Exane Operator Ladies and gentlemen, thank you for standing by.

Fresenius Medical Care AG & Co. KGaA (FMS) Q2 2023 Earnings Call Transcript

Organic growth accelerated in the second quarter in Care Enablement and Care Delivery including sequentially stable treatment volumes in the U.S. Execution on turnaround plan translates into visible productivity improvements in Care Delivery achieving a Q2 margin at the lower end of the 2025 target margin band Savings resulting from FME25 transformation program fully on track Successful execution on portfolio optimization strategy Legal form conversion to a German Stock Corporation approved by shareholders FY 2023 operating income guidance range narrowed WALTHAM, Mass. , Aug. 2, 2023 /PRNewswire/ -- Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: "The second quarter makes evident that the execution against our strategic plan is fully on track.

Fresenius Medical Care successfully executes strategic plan and narrows guidance range due to strong operational performance in the first half of 2023

Fresenius Medical Care is the world's leading full-service provider of dialysis care and benefits from the entire value chain thanks to its vertical integration. Despite its market-leading position, Fresenius has been a poor performer, with disappointing returns on invested capital and high turnover rates pointing to internal problems. The article takes a look at Fresenius' operational challenges and provides an update on the company's balance sheet against the backdrop of the current interest rate environment.

Fresenius Medical Care: Heads Don't Roll - They Run

The move is meant to allow better and timelier decision-making. Fresenius operates dialysis facilities across the world.

Why Shares of Fresenius Medical Jumped This Week

Extraordinary General Meeting approves conversion of Fresenius Medical Care's legal form Several advantages including faster and more agile decision-making Michael Sen elected as Chair of new Supervisory Board Conversion expected to be completed by the end of 2023 WALTHAM, Mass., July 14, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, held an Extraordinary General Meeting (EGM) today.

Fresenius Medical Care simplifies corporate structure by converting into a German stock corporation

Fresenius Medical Care said on Friday that shareholders voted with a 99.88% majority in favour of a change that will simplify its governance and make parent Fresenius SE a regular minority shareholder.

Fresenius Medical shareholders approve change in legal form

Under the U.S. Securities Act of 1933, as amended (the "Securities Act"), this press release may be deemed to be offering material of Fresenius Medical Care AG & Co. KGaA ("FME"). FME has filed a registration statement on Form F-4 under the Securities Act with the U.S. Securities and Exchange Commission (the "SEC"), including an information statement/prospectus constituting a part thereof.

Fresenius Medical Care appoints Martin Fischer as Chief Financial Officer

Shares in kidney dialysis group Fresenius Medical Care declined 1.7% at market open in Germany on Tuesday after a payment increase proposed by a major U.S. public health insurance body fell short of market expectations.

Fresenius Medical Care shares drop on U.S. dialysis payment adjustment

Fresenius Medical Care has shown some improvement in recent trends, but still faces headwinds and pressures in its markets. Analysts have consistently underestimated FMS's performance, and I think the company has a potential upside of 15% annually or 44% until 2025E. However, the native Fresenius ticker may be a better investment due to its diversification and better fundamentals, depending on your goals.

Fresenius Medical Care: Other Stocks Still Better, But Upside Exists

Fresenius Medical's (FMS) first-quarter revenues benefit from strong performances across all segments, especially the North America and Asia-Pacific regions. However, rising costs hurt margins.

Fresenius Medical (FMS) Q1 Earnings and Revenues Beat Estimates

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS ) Q1 2023 Earnings Conference Call May 9, 2023 9:30 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chair, Chief Executive Officer & Acting Chief Financial Officer Conference Call Participants Victoria Lambert - Berenberg Hassan Al-Wakeel - Barclays Veronika Dubajova - Citi Oliver Metzger - ODDO Robert Davies - Morgan Stanley David Adlington - JPMorgan James Vane-Tempest - Jefferies Lisa Clive - AB Bernstein Christoph Gretler - CS Sezgi Ozener - HSBC Operator Ladies and gentlemen, thank you for standing by. I'm Timo your Chorus Call operator.

Fresenius Medical Care AG & Co. KGaA (FMS) Q1 2023 Earnings Call Transcript

What to "BUY" in this time of absolute turmoil is something to be carefully considered. I try to focus on undervalued, qualitative opportunities. These exist in every sector. Fresenius has long been a position of mine. In this article, I seek to update what's happened to the Medical Care wing, with the FMS symbol.

Fresenius Medical Care: Attractive Post Crash, Maintaining A 'Buy' Rating

Fresenius Medical's (FMS) fourth-quarter revenues benefit from strong performance across all segments, especially in the North America and Asia-Pacific regions. However, rising costs hurt margins.

Fresenius Medical's (FMS) Q4 Earnings and Revenues Beat

Energy Transfer LP Unit

Organon & Co

Taro Pharmaceutical Industries

Teva Pharmaceutical

Viatris

Francisco Garcia Parames' Cobas Funds 4th-Quater Letter

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS ) Q4 2022 Earnings Conference Call February 22, 2023 9:30 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chair & Chief Executive Officer Conference Call Participants Graham Doyle - UBS Hassan Al-Wakeel - Barclays Oliver Metzger - ODDO BHF Christoph Gretler - CS Ed Ridley-Day - Redburn Lisa Clive - Bernstein James Vane-Tempest - Jefferies Victoria Lambert - Berenberg Falko Friedrichs - Deutsche Bank Robert Davies - Morgan Stanley Operator Ladies and gentlemen, thank you for standing by. I am Nicolas, your Chorus Call operator.

Fresenius Medical Care AG & Co. KGaA (FMS) Q4 2022 Earnings Call Transcript

AbbVie

Alvotech SA

Amgen

Bristol-Myers

Coherus BioSciences

Cigna

CVS Health

GlaxoSmithKline

Johnson & Johnson

Merck

Novo Nordisk

Novartis

Pfizer

Regeneron Pharmaceuticals

Roche Holding AG

Sanofi

It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.

Competition Coming For AbbVie's Blockbuster Humira

WALTHAM, Mass. , Jan. 20, 2023 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has taken the Zero Health Gaps Pledge at the World Economic Forum in Davos, Switzerland.

Fresenius Medical Care takes action to close global health gaps, signs "Zero Health Gaps" Pledge at the World Economic Forum

I've been unfailingly bullish in the long-term on Fresenius - both the medical care, but also the main company headquartered in Germany. Fresenius has had an extremely tricky set of years, due to company challenges and what could be characterized as mismanagement (without being wrong).

Fresenius: The Company Is Climbing, And I'm At 'Buy'

Enbridge

Essex Property Trust

First of Long Island

Federal Realty Investment Trust

Leggett & Platt

Altria

Stanley Black & Decker

V.F.

Dividend growth blue-chips are the best performing assets in history. There are no more dependable dividend growth blue-chips for the 2023 recession than dividends aristocrats.

The 9 Best 4+% Yielding Dividend Aristocrats For 2023

News for Fresenius Medical Care Stock (FMS)